iX Biopharma: Restructures Consumer Business, Advances Joint Venture Discussions with Orion Specialty Labs

NewTimeSpace News: On May 11, 2026, iX Biopharma Ltd. announced that it will undertake an internal restructuring of its consumer business, consolidating its Australian and Hong Kong subsidiaries, approximately 40 WaferiX-based formulations, and the direct-to-consumer telehealth platform currently under development under a newly incorporated holding company, Ligo Pharma Pte Ltd.

Following the restructuring, iX will own 100% of Ligo, and Ligo will hold the consumer-facing assets and the commercial licence to iX‘s WaferiX sublingual delivery technology. The Wafermine drug product, its associated regulatory assets, and the US Department of Defence contract obligations remain with iX and are unaffected by the restructuring.

iX Biopharma stated that the US 503A/B compounding regulatory framework allows approximately 40 of its formulations to be commercialised immediately, without waiting for FDA approval. Meanwhile, the Company is in advanced discussions with GLD and Orion regarding a proposed joint venture, intending to incorporate Orion into the Ligo structure, with GLD becoming a co-shareholder of Ligo.

NewTimeSpace Disclaimer: All content herein is the original work of NewTimeSpace. Any reproduction, reprinting, or use of this content in any other manner must clearly indicate the source as "NewTimeSpace". NewTimeSpace and its authorized third-party information providers strive to ensure the accuracy and reliability of the data, but do not guarantee the absolute correctness thereof. This content is for reference only and does not constitute any investment advice. All transaction risks shall be borne by the user.